X0306 4 2020-02-24 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001550395 ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Global Research and CSO Common Stock 2020-02-24 4 F 0 2416 239.23 D 31930 D Common Stock 2020-02-25 4 S 0 734 229.72 D 31196 D Common Stock 2020-02-25 4 S 0 400 230.77 D 30796 D Common Stock 2020-02-25 4 S 0 400 232.51 D 30396 D Common Stock 2020-02-25 4 S 0 574 234.52 D 29822 D Common Stock 2020-02-25 4 S 0 280 235.53 D 29542 D Common Stock 2020-02-25 4 S 0 160 236.80 D 29382 D Common Stock 2020-02-25 4 S 0 480 238.33 D 28902 D Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.14). Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $230.77 (range $230.29 to $231.27). Open market sales reported on this line occurred at a weighted average price of $232.51 (range $232.33 to $233.04). Open market sales reported on this line occurred at a weighted average price of $234.52 (range $234.22 to $234.82). Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.43 to $235.72). Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.54). /s/ Omar White, Attorney-in-Fact 2020-02-26